AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead

The partnership that brought Enhertu to the market is gearing up for another potential breast cancer blockbuster. AstraZeneca and Daiichi Sankyo announced positive high-level Phase III results for their TROP2-directed antibody-drug conjugate Friday, with plans for regulatory submissions underway.